Skip to main content

Animations

MJFF Publications

6071 - 6080 of 9140 Results
Title
Year
  • Year
  • 2026
  • 2023
  • 2023
  • 2022
  • 2025
  • 2024
  • 2026
  • 2022
  • 2025
  • 2025
  • Summary Details
    OPEN
    Title: Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1093/brain/awag001
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29563
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Ethnicity and Parkinson’s Disease: Motor and Nonmotor Features and Disease Progression in Latino Patients Living in Rural California
    Journal Name: The Journals of Gerontology: Series A
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1093/gerona/glad016
    Citation Count: 13
  • Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?
    2022
    Summary Details
    RESTRICTED
    Title: Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.29058
    Citation Count: 20
  • Summary Details
    OPEN
    Title: The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D study
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1177/1877718x251407026
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Die Vermehrung von Alpha‐Synuclein Amyloidfibrillen ist unterdrückt unter vollständig ruhenden Lösungsbedingungen
    Journal Name: Angewandte Chemie
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/ange.202419173
    Citation Count: 0
  • Summary Details
    OPEN
    Title: VGLUT2 in Parkinson’s disease: an emerging therapeutic target
    Journal Name: Expert Opinion on Therapeutic Targets
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1080/14728222.2026.2619754
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Subcellular Fractionation for the Isolation of Synaptic Components from the Murine Brain
    Journal Name: Journal of Visualized Experiments
    Publisher: MyJove Corporation
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.3791/64574
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice
    Journal Name: Experimental Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.expneurol.2025.115502
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Epigenetic ageing and the risk of Parkinson’s disease
    Journal Name: Journal of Neurology, Neurosurgery & Psychiatry
    Publisher: BMJ
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1136/jnnp-2025-336802
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.